The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2016 | Multiple myeloma depth of response to therapy at different stages
Faith Davies, MD, of the University of Arkansas for Medical Sciences, Fayetteville, AR, outlines her highlights in multiple myeloma (MM), discussing the importance of depth of response to multiple myeloma therapy. A UK study has shown that further induction therapy prior to transplant can be more successful than proceeding to transplantation in patients who didn’t have a good response to first induction therapy. A US and a European study looked at the role of consolidation therapy post-transplantation. However, the results for these studies are conflicting. Dr Davies concludes that moving forward, it is important to make sure that depth of response is improved in each treatment section. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
